Vitura SA (FR:VTR)
:VTR
Top Page
Vitura SA
(VTR)
Select Model
Select Model
Rating:43Neutral
Price Target:
€5.00
▼(-9.91% Downside)
Action:ReiteratedDate:11/30/25
Vitura SA's overall stock score of 43 reflects significant challenges, primarily driven by poor financial performance with persistent net losses, declining revenue, and high leverage. Technical analysis further supports a bearish outlook with a consistent downtrend and weak momentum. Valuation metrics offer no positive offset due to negative earnings and lack of dividend yield.
Positive Factors
Innovation and R&D
Vitura SA's commitment to R&D fosters innovation, enabling the development of advanced medical products and solutions, which can lead to sustainable competitive advantages and long-term growth.
Negative Factors
Declining Revenues
Declining revenues indicate potential challenges in maintaining market share and demand for products, which can impact long-term financial health and growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovation and R&D
Vitura SA's commitment to R&D fosters innovation, enabling the development of advanced medical products and solutions, which can lead to sustainable competitive advantages and long-term growth.
Read all positive factors
Vitura SA (VTR) vs. iShares MSCI France ETF (EWQ)
Market Cap
€81.90M
Dividend YieldN/A
Average Volume (3M)364.00
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth-7.84%
EPS Growth71.75%
CountryFR
Employees2
SectorServices
Sector StrengthN/A
IndustryREIT - Office
Share Statistics
EPS (TTM)-0.58
Shares Outstanding17,087,708
10 Day Avg. Volume318
30 Day Avg. Volume364
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vitura SA Business Overview & Revenue Model
Company Description
Vitura SA (VTR) is a leading company operating in the healthcare and pharmaceuticals sector, specializing in the development, manufacturing, and distribution of innovative medical products and solutions. The company focuses on enhancing patient ca...
How the Company Makes Money
Vitura SA generates revenue through multiple streams, primarily from the sale of its pharmaceutical products and medical devices. The company has established a strong market presence through strategic partnerships with healthcare providers, hospit...
Vitura SA Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
25
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.14M | 60.32M | 57.87M | 76.61M | 72.78M | 84.92M |
| Gross Profit | 36.88M | 37.76M | 32.91M | 50.43M | 44.14M | 63.67M |
| EBITDA | 17.07M | 21.86M | 26.85M | -166.93M | 41.01M | 45.52M |
| Net Income | -199.38M | -20.75M | -243.00M | -239.85M | -4.18M | 36.93M |
Balance Sheet | ||||||
| Total Assets | 936.33M | 920.92M | 940.47M | 1.40B | 1.62B | 1.66B |
| Cash, Cash Equivalents and Short-Term Investments | 23.36M | 21.64M | 13.49M | 11.72M | 15.17M | 57.48M |
| Total Debt | 643.20M | 644.69M | 644.20M | 855.10M | 835.39M | 833.49M |
| Total Liabilities | 678.38M | 672.77M | 671.57M | 883.93M | 868.77M | 890.52M |
| Stockholders Equity | 257.95M | 248.15M | 268.91M | 511.91M | 755.44M | 772.94M |
Cash Flow | ||||||
| Free Cash Flow | 18.23M | 3.99M | 3.83M | -17.45M | -22.70M | -69.37M |
| Operating Cash Flow | 22.40M | 11.38M | 12.61M | 12.04M | -9.36M | 40.90M |
| Investing Cash Flow | 1.08M | -7.51M | -2.69M | -29.32M | -19.47M | -103.31M |
| Financing Cash Flow | -10.50M | -1.06M | -8.15M | 13.83M | -13.48M | 57.05M |
Vitura SA Technical Analysis
Positive
5.55
Price Trends
3.87
Positive
3.81
Positive
4.77
Negative
Market Momentum
0.09
Negative
81.24
Negative
75.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VTR, the sentiment is Positive. The current price of 5.55 is above the 20-day moving average (MA) of 3.92, above the 50-day MA of 3.87, and above the 200-day MA of 4.77, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 81.24 is Negative, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VTR.
Vitura SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | €65.38M | 6.23 | 18.06% | 0.55% | 6.71% | 7.79% | |
72 Outperform | €579.70M | 19.04 | 12.71% | 2.54% | 1.02% | 6.31% | |
60 Neutral | €181.71M | 19.39 | -5.44% | ― | 3.79% | -797.10% | |
57 Neutral | €1.88B | 23.95 | 6.98% | 2.08% | -0.23% | -37.70% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% | |
43 Neutral | €81.90M | -2.58 | -16.98% | ― | -7.84% | 71.75% | |
41 Neutral | €38.17M | 6.33 | ― | ― | -0.95% | 49.19% |
* Services Sector Average
FR:VTR
Vitura SA
4.80
-2.75
-36.42%
FR:ATE
ALTEN SA
53.85
-21.92
-28.93%
FR:AUB
Aubay Société Anonyme
45.55
4.55
11.09%
FR:ALCLA
Claranova SA
0.67
-1.38
-67.24%
FR:ALCGM
Cegedim
13.25
2.70
25.59%
FR:COH
Coheris
11.50
4.47
63.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.